MODE OF ACTION
Traditional laxatives such as osmotics or faecal softeners stimulate the bowel but do not treat the underlying cause of the problem with recent studies indicating that some 30% to 50% of all chronic opioid patients are unable to obtain relief from such treatments.
Nalolax works by blocking the mu-opioid receptors in the gut with two key effects:
- As a pure opioid anatagonist it combats the constipating effect of the opioid.
- Naloxone has a low systemic bioavailability (<1%), so it does not antagonise the central analgesic effect of the opioid.
Nalolax has a clear defined patient benefit. It is highly effective in reversing opioid-induced constipation and is suitable for use in both long-term and acute situations.
- Titratable to patient needs.
- Low side effect profile.
- Can be prescribed with commonly used opioids at the recommended doses.